Intellia Therapeutics (NTLA) Projected to Post Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) will likely be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.99) per share and revenue of $12.1730 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 12:30 PM ET.

Intellia Therapeutics Price Performance

NTLA stock opened at $12.48 on Thursday. The stock has a market capitalization of $1.45 billion, a P/E ratio of -2.92 and a beta of 2.10. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. The business has a fifty day moving average price of $11.29 and a 200-day moving average price of $12.93.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 10,397 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the sale, the executive vice president owned 101,528 shares of the company’s stock, valued at approximately $935,072.88. The trade was a 9.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the sale, the executive vice president owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. The trade was a 7.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 53,051 shares of company stock worth $488,600. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Large investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC boosted its position in shares of Intellia Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after purchasing an additional 2,288,146 shares during the period. State Street Corp boosted its holdings in Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock worth $57,705,000 after buying an additional 1,447,967 shares during the period. Geode Capital Management LLC boosted its holdings in Intellia Therapeutics by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock worth $24,243,000 after buying an additional 107,333 shares during the period. Two Sigma Investments LP raised its holdings in Intellia Therapeutics by 7.6% during the third quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock valued at $42,305,000 after acquiring an additional 173,033 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Intellia Therapeutics by 9.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,931,849 shares of the company’s stock valued at $17,367,000 after acquiring an additional 174,555 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on NTLA shares. William Blair lowered Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 27th. Chardan Capital decreased their price objective on shares of Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating for the company in a report on Friday, November 7th. JPMorgan Chase & Co. restated an “underweight” rating and issued a $5.00 target price (down previously from $12.00) on shares of Intellia Therapeutics in a report on Friday, November 7th. Wells Fargo & Company decreased their target price on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th. Finally, Sanford C. Bernstein set a $14.50 price target on Intellia Therapeutics in a research note on Tuesday, October 28th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics has a consensus rating of “Hold” and an average target price of $17.48.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.